The risk of MDS/AML from PARP inhibitors is low (<0.5%) in frontline ovarian cancer but rises to 2-8% in second-line settings. This is likely due to cumulative DNA damage from multiple lines of platinum chemotherapy, not just the PARP inhibitor itself, informing risk-benefit discussions.
Instead of providing a single prognosis at diagnosis, clinicians can use conditional survival data from clinical trials. For example, telling a patient who is progression-free at 3 years that they now have a 92% chance of remaining so at 4 years offers a powerful and reassuring counseling tool.
While numerous antibody-drug conjugates (ADCs) with different targets are in development for ovarian cancer, most use a topoisomerase inhibitor payload. This creates a future clinical challenge, as patients may become resistant to the payload class, limiting the effectiveness of subsequent ADCs regardless of the target.
The new agent relicorolant works by blocking the glucocorticoid receptor, which is linked to chemotherapy resistance. This raises the critical question of whether the standard practice of giving steroids before paclitaxel infusion to prevent side effects could be unintentionally hampering treatment efficacy.
Data increasingly shows ovarian cancer originates in the fallopian tubes, not ovaries. Opportunistic salpingectomy (tube removal) during procedures like C-sections or appendectomies significantly reduces cancer risk without inducing premature menopause, shifting preventative care paradigms.
The DUO-E trial found that adding a PARP inhibitor to immunotherapy/chemotherapy did not benefit mismatch repair deficient (dMMR) endometrial cancer patients. However, it significantly improved outcomes for the harder-to-treat mismatch repair proficient (pMMR) population, defining a specific role for this combination.
The Rosella study of relicorolant showed a striking overall survival (OS) benefit despite a modest progression-free survival (PFS) gain. This unusual pattern, often seen with immunotherapies, suggests the drug may have a delayed or immune-mediated effect beyond immediate tumor control, challenging traditional efficacy endpoints.
For managing the ocular toxicity associated with the ADC mirvetuximab, an optometrist is a sufficient and often more accessible alternative to an ophthalmologist. This practical insight simplifies care logistics for patients and oncology practices, improving access to necessary monitoring.